Accessibility Menu
 
Pulmonx logo

Pulmonx

(NASDAQ) LUNG

Current Price$1.29
Market Cap$54.49M
Since IPO (2020)-97%
5 Year-97%
1 Year-81%
1 Month-16%

Pulmonx Financials at a Glance

Market Cap

$54.49M

Revenue (TTM)

$90.50M

Net Income (TTM)

$54.00M

EPS (TTM)

$-1.33

P/E Ratio

-0.97

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$1.29

Volume

183,051

Open

$1.27

Previous Close

$1.28

Daily Range

$1.25 - $1.35

52-Week Range

$1.13 - $7.05

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pulmonx

Industry

Healthcare Equipment and Supplies

Employees

296

CEO

Glendon E. French, MBA

Headquarters

Redwood City, CA 94063, US

LUNG Financials

Key Financial Metrics (TTM)

Gross Margin

74%

Operating Margin

-59%

Net Income Margin

-60%

Return on Equity

-77%

Return on Capital

-49%

Return on Assets

-42%

Earnings Yield

-1.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$54.49M

Shares Outstanding

42.24M

Volume

183.05K

Short Interest

0.00%

Avg. Volume

511.01K

Financials (TTM)

Gross Profit

$67.14M

Operating Income

$53.66M

EBITDA

$52.61M

Operating Cash Flow

$32.45M

Capital Expenditure

$452.00K

Free Cash Flow

$32.90M

Cash & ST Invst.

$70.01M

Total Debt

$56.36M

Pulmonx Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$22.60M

-4.9%

Gross Profit

$17.54M

-0.3%

Gross Margin

77.62%

N/A

Market Cap

$54.49M

N/A

Market Cap/Employee

$187.24K

N/A

Employees

291

N/A

Net Income

$10.43M

+20.9%

EBITDA

$9.90M

+24.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$13.64M

-69.7%

Accounts Receivable

$12.07M

-12.5%

Inventory

$15.85M

-6.3%

Long Term Debt

$55.05M

+4.8%

Short Term Debt

$1.32M

-66.7%

Return on Assets

-41.77%

N/A

Return on Invested Capital

-49.13%

N/A

Free Cash Flow

$7.10M

-3.7%

Operating Cash Flow

$7.08M

-5.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCRXTScan Therapeutics, Inc.
$1.03+1.98%
ACRVAcrivon Therapeutics, Inc. Common Stock
$1.46+5.04%
PMVPPMV Pharmaceuticals, Inc.
$1.33+7.26%
TELATELA Bio, Inc.
$0.57-8.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics
$6.38+3.12%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.23+0.04%
NKENike
$44.63-0.16%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.45-0.01%

Questions About LUNG

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.